News
Posts are organized into categories for ease of navigation:
- Algorithm - developments to the interpretation algorithm implemented in Python.
- Announcement - general news related to the Molecular Oncology Almanac.
- Database - changes and additions to the underlying knowledge base.
- Release - aggregated release notes from GitHub releases (serving as the project changelog).
-
Database release
Added entries:
- (FDA) BRCA1 and BRCA2 somatic and germline variants and sensitivity to olaparib in combination with abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer.
- (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib for patients with metastatic pancreatic adenocarcinoma.
- (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib for the treatment of adult patients with HER2-negative high risk early breast cancer.
- (FDA) ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C somatic variants and sensitivity to talazoparib in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer.
-
Algorithm release 0.4.6
This release utilizes the v.2023-04-06 release of the underlying MOAlmanac database. It incorporates changes from two pull requests: #13 and #14.
Continue reading -
Database release
Added entries:
- (FDA) BRAF p.V600E and sensitivity to dabrafenib in combination with trametinib for pediatric patients with low-grade glioma.
-
Algorithm release 0.4.5
This release utilizes the v.2023-02-02 release of the underlying MOAlmanac database. It incorporates changes from three pull requests: changing the underlying MOAlmanac database from TinyDB to JSON (#9), adding a simplified input option to run MOAlmanac (#10), and updating datasources (#11).
Continue reading -
Database release
In this release, we add two recent precision oncology approvals from the FDA regarding ER signaling inhibition in two cancer types.
Continue reading